Securinega Virosa (Flueggea virosa): Benefits, Dosage, Safety & Evidence

Questions fréquentes

How does Securinega virosa work in the body?

Securinega virosa contains securinine, a primary alkaloid that acts as a central nervous system stimulant and has demonstrated antimalarial and antimicrobial properties in laboratory studies. The plant's flavonoids contribute antioxidant and anti-inflammatory effects, while other alkaloids like norsecurinine may support wound healing through tissue regeneration. Evidence level: C (preclinical studies and traditional use). The exact mechanisms require further clinical investigation.

Does Securinega virosa interact with any medications?

Securinega virosa may interact with medications affecting the central nervous system due to securinine's stimulant properties. It could potentially interfere with cardiac medications, as high doses have been associated with cardiac effects. Those taking antimalarial drugs should consult a healthcare provider before combining treatments. Evidence level: C. Always inform your healthcare provider about all herbal supplements you are taking to avoid potential interactions.

What is the recommended dosage for Securinega virosa?

Traditional adult dosages include a bark decoction of 200ml taken 2-3 times daily for internal use. For external skin conditions, a leaf paste can be applied topically to affected areas. Dosage should be prepared by experienced practitioners, as potency varies by preparation method. Evidence level: C (traditional use). Always start with lower doses and consult a qualified herbalist or healthcare provider for personalized guidance.

Is Securinega virosa safe during pregnancy?

Securinega virosa is considered unsafe during pregnancy and should be strictly avoided. The plant contains securinine, which has uterine-stimulating properties and may cause miscarriage or harm fetal development. Traditional contraindications explicitly list pregnancy as a condition to avoid use. Women who are breastfeeding should also avoid this herb. Evidence level: C. Consult a healthcare provider for safe alternatives during pregnancy.

Can Securinega virosa treat malaria?

Securinega virosa has been used traditionally across tropical Africa for malaria treatment, and laboratory studies show that securinine and related compounds have antimalarial activity against Plasmodium species. However, clinical trials in humans are lacking. Evidence level: C. This herb should not replace conventional antimalarial medications without medical supervision, as untreated malaria can be life-threatening. Consult a healthcare provider for proper diagnosis and treatment.

What are the side effects of Securinega virosa?

Common side effects include nausea, particularly when taken as an emetic. At high doses, securinine can cause cardiac effects including arrhythmias and central nervous system overstimulation. The plant should not be used by individuals with cardiac conditions or children under 6 years old. Evidence level: C. Discontinue use if you experience irregular heartbeat, dizziness, or severe gastrointestinal symptoms, and seek medical attention.

Fiche d'information compilée à partir de PubMed

Cette fiche a été compilée à partir de résumés PubMed (NIH) avec l'assistance d'une IA. Chaque affirmation factuelle est citée par un article PubMed réel (voir la liste des sources). Elle n'a pas encore été révisée par un humain — confirmez auprès d'un professionnel de santé avant utilisation.

Compilé à partir de 30 articles PubMed · modèle : gemma4:31b

Résumé

Securinega virosa (also known as Flueggea virosa) is an evergreen shrub or small tree in the Phyllanthaceae family with significant pharmacological potential [PMID:39138223, PMID:33457893].

Contexte

Flueggea virosa is a tropical plant used in traditional medicine across Africa and Asia [PMID:38732484, PMID:33457893]. It is characterized as an evergreen shrub and small tree [PMID:39138223].

Usages traditionnels

The plant is used in traditional medicine for the management of parasite infections, diabetes, gastrointestinal diseases [PMID:38732484], mental illnesses, epilepsy [PMID:22353430, PMID:26693416], and as a sedative in children [PMID:20161930]. It is also recommended by traditional therapists in Burkina Faso for treating periodontitis [PMID:38371022] and used in Uganda for the treatment of snakebites [PMID:32071543].

Composés actifs

Active constituents include alkaloids (such as fluevirines, flueindolines, flueggines, and norsecurinine) [PMID:30721084, PMID:32451096, PMID:16706507, PMID:38732484], terpenoids (including dinorditerpenoids like flueggenoids and podovirosanes) [PMID:30605781, PMID:36500641], and phenolic compounds such as bergenin and menisdaurin [PMID:30416355, PMID:25662964].

Mécanisme d'action

Certain alkaloids (fluevirosines A-H and fluevirosinine A-J) are predicted via molecular docking to bind to the tubulin dimer [PMID:38732484]. Podovirosanes A-F and a polyketide have been shown to reduce the phosphorylation levels of NF-κB p65 in SARS-CoV-2 pseudovirus-stimulated cells [PMID:36500641]. Some fractions may inhibit the heme polymerization pathway of malaria parasites [PMID:28273638].

Preuves cliniques

Preuve DHepatitis C Virus (HCV)

Various terpenoids and dinorditerpenes (e.g., compounds 1, 3, 11, 12) exhibited significant anti-HCV activity in vitro [PMID:30605781, PMID:24400834, PMID:27112277].

Preuve DMalaria

Hydro-ethanolic extracts and bergenin showed potential antimalarial activity against Plasmodium falciparum and P. berghei in vitro and in mice [PMID:28273638].

Preuve DCancer

Certain alkaloids (e.g., flueggine B) showed growth inhibitory activity against human breast cancer cell lines (MCF-7 and MDA-MB-231) [PMID:21728296].

Preuve DSleep/Sedation

Methanolic root bark extract and bergenin significantly reduced the onset and prolonged the duration of sleep in mice [PMID:20161930, PMID:26693416].

Preuve DSickle Cell Anaemia

Aqueous and ethanolic extracts of the aerial part showed anti-sickle cell activity in vitro using the Emmel technique [PMID:37895986].

Preuve DHIV

Sécurité et effets indésirables

In mice, the intraperitoneal median lethal dose (LD50) of the methanolic root bark extract was 774.6 mg/kg [PMID:20161930]. The extract also produced dose-dependent motor coordination deficits in mice [PMID:20161930].

Synthèse des preuves

The current evidence is primarily based on in vitro studies and animal models (Level D), focusing on phytochemical isolation and preliminary pharmacological screening. There are no human clinical trials provided in the abstracts.

Sources PubMed

1.PMID: 30605781 (2019) — Flueggenoids A - E, new dinorditerpenoids from Flueggea virosa. · Fitoterapia
2.PMID: 30721084 (2020) — Fluevirines E and F, two new alkaloids from Flueggea virosa. · Natural product research
3.PMID: 38371022 (2024) — The Potential of Cochlospermum tinctorium, Flueggea virosa, and Waltheria indica Traditional Plants From Burkina Faso in Treating Periodontitis: A Systematic Review. · Cureus
4.PMID: 39138223 (2024) — Chromosome-level genome assembly and annotation of Flueggea virosa (Phyllanthaceae). · Scientific data
5.PMID: 32451096 (2020) — Alkaloid constituents from the fruits of Flueggea virosa. · Chinese journal of natural medicines

Securinega Virosa

Sources et citations

Calculer une dose sûre de Securinega Virosa